Get started
Zymeworks Inc.Zymeworks Inc.Zymeworks Inc.

Zymeworks Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Options

ZYME chart


Full chart

ZYME upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪767.41 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−1.62 USD
Net income (FY)
‪−122.69 M‬ USD
Revenue (FY)
‪76.30 M‬ USD
Shares float
‪67.30 M‬
Beta (1Y)
1.39

Employees


Employees (FY)
286
Change (1Y)
+9 +3.25%
Revenue / Employee (1Y)
‪266.80 K‬ USD
Net income / Employee (1Y)
‪−429.00 K‬ USD

About Zymeworks Inc.


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Kenneth Harry Galbraith
Website
zymeworks.com
Headquarters
Middletown
Founded
2003
FIGI
BBG019XSYC89
Zymeworks, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Its product includes Zanidatamab, which is a novel bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Zanidatamab's unique binding properties result in multiple mechanisms of action that may enable it to address unmet need in patient populations with HER2-expressing cancers. The company was founded on September 8, 2003 and is headquartered in Middletown, DE.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

ZYME news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Check out other big names from the same industry as ZYME.

Frequently Asked Questions


The current price of ZYME is 11.01 USD — it has decreased by −0.55% in the past 24 hours. Watch Zymeworks Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Zymeworks Inc. stocks are traded under the ticker ZYME.
ZYME stock has fallen by −1.08% compared to the previous week, the month change is a −15.55% fall, over the last year Zymeworks Inc. has showed a 22.61% increase.
We've gathered analysts' opinions on Zymeworks Inc. future price: according to them, ZYME price has a max estimate of 30.00 USD and a min estimate of 12.00 USD. Watch ZYME chart and read a more detailed Zymeworks Inc. stock forecast: see what analysts think of Zymeworks Inc. and suggest that you do with its stocks.
ZYME reached its all-time high on Jan 12, 2021 with the price of 59.03 USD, and its all-time low was 4.11 USD and was reached on Sep 7, 2022. View more price dynamics on ZYME chart.
See other stocks reaching their highest and lowest prices.
ZYME stock is 3.55% volatile and has beta coefficient of 1.39. Track Zymeworks Inc. stock price on the chart and check out the list of the most volatile stocks — is Zymeworks Inc. there?
Today Zymeworks Inc. has the market capitalization of ‪767.41 M‬, it has decreased by −14.89% over the last week.
Yes, you can track Zymeworks Inc. financials in yearly and quarterly reports right on TradingView.
Zymeworks Inc. is going to release the next earnings report on Apr 30, 2025. Keep track of upcoming events with our Earnings Calendar.
ZYME earnings for the last quarter are −0.31 USD per share, whereas the estimation was −0.099 USD resulting in a −211.88% surprise. The estimated earnings for the next quarter are −0.68 USD per share. See more details about Zymeworks Inc. earnings.
Zymeworks Inc. revenue for the last quarter amounts to ‪31.03 M‬ USD, despite the estimated figure of ‪45.20 M‬ USD. In the next quarter, revenue is expected to reach ‪20.61 M‬ USD.
ZYME net income for the last quarter is ‪−23.51 M‬ USD, while the quarter before that showed ‪−29.85 M‬ USD of net income which accounts for 21.25% change. Track more Zymeworks Inc. financial stats to get the full picture.
No, ZYME doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Apr 16, 2025, the company has 286 employees. See our rating of the largest employees — is Zymeworks Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Zymeworks Inc. EBITDA is ‪−108.63 M‬ USD, and current EBITDA margin is −142.36%. See more stats in Zymeworks Inc. financial statements.
Like other stocks, ZYME shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Zymeworks Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Zymeworks Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Zymeworks Inc. stock shows the sell signal. See more of Zymeworks Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.